the COB: weighed down
the COB: weighed down
About this video
The market closed in the green today, but CSL weighed on potentially bigger gains. The share price was down by over 5% on news that a trial of weight loss drug Ozempic in kidney disease delivered good results. CSL's ViFor business- which it recently acquired for $16 billion- works in this space, apparently concerning investors. The rest of the healthcare sector was a mixed bag.
Asian shares rose on as markets wagered that U.S. rates have peaked after more dovish remarks from Federal Reserve officials, while traders awaited the U.S. consumer inflation report later in the day for further monetary policy clues. MSCI's broadest index of Asia-Pacific shares outside Japan gained 0.7% to the highest level in three weeks. Tokyo's Nikkei rallied 1.3% for a third straight day, climbing away from its five-month low hit last week.
Minutes of the Fed's Sept. 19-20 meeting showed policymakers wrestling with risks they agreed were no longer just about inflation, with world energy and food markets perhaps threatening a new surge in prices, but slowing global growth, labor strikes and tightening financial markets possibly clamping down on the economy in unexpected, and job-killing ways.
Overnight, attention turns to US inflation and jobless claims and UK GDP. Boston Fed President Collins is als scheduled to speak, which will be watched closely by markets.